Biotechnology firm Exelixis Inc. said Thursday it has agreed to license certain compounds for metabolic disorders to pharmaceutical giant Wyeth for an upfront fee of $10 million. Exelixis, which develops therapeutics for cancer and other diseases, may receive up to $147.5 million in development and commercialization milestones and royalties on the sale of commercialized products.

MSN Money (http://news.moneycentral.msn.com/provider/providerarticle.asp?feed=AP&Date=20051222&ID=5374444)